This study intended to examine patients’ preferences for attributes of postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of treatment with letrozole or anastrozole and to estimate their WTP for the treatments. This evidence concerns the gene NR4A1 and breast cancer.